Effect of gatifloxacin against Mycoplasma genitalium-related urethritis: an open clinical trial.
Author(s): Hamasuna R, Takahashi S, Kiyota H, Yasuda M, Hayami H, Arakawa S, Tomono K, Matsumoto T
Affiliation(s): Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 807-8555, Japan. hamaryo@med.uoeh-u.ac.jp
Publication date & source: 2011-08, Sex Transm Infect., 87(5):389-90. Epub 2011 Apr 28.
Publication type: Clinical Trial; Research Support, Non-U.S. Gov't
OBJECTIVES: Mycoplasma genitalium and Chlamydia trachomatis are the primary pathogens detected from non-gonococcal urethritis (NGU). In this study, the efficacy of gatifloxacin was examined against M genitalium-related urethritis. METHODS: The study was an open clinical trial evaluating the effectiveness of gatifloxacin with 200 mg doses twice a day for 7 days against male NGU. RESULTS: Between March and September 2008, 169 male patients were enrolled, and microbiological and clinical cure rates could be evaluated in 86 patients detected with C trachomatis or M genitalium and in 135 with NGU, respectively. Microbiological cure rates of gatifloxacin against C trachomatis and M genitalium were 100% and 83%, respectively, and the total clinical cure rate was 99%. CONCLUSION: Analysis of in-vivo and in-vitro data from the literature of fluoroquinolone efficacies against M genitalium suggests that a MIC90 of 0.125 mug/ml or less may be useful for optimal activity against M genitalium infection.
|